Prosecution Insights
Last updated: November 04, 2026
Application No. 18/637,627

SIGLEC-9 ECD Fusion Molecules and Methods of Use Thereof

Non-Final OA §112
Filed
Apr 17, 2024
Priority
Nov 04, 2019 — provisional 62/930,227 +3 more
Examiner
STOICA, ELLY GERALD
Art Unit
1647
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Alector LLC
OA Round
1 (Non-Final)
67%
Grant Probability
Favorable
1-2
OA Rounds
0m
Est. Remaining
89%
With Interview

Examiner Intelligence

Grants 67% — above average
67%
Career Allowance Rate
833 granted / 1247 resolved
+6.8% vs TC avg
Strong +23% interview lift
Without
With
+22.6%
Interview Lift
resolved cases with interview
Typical timeline
2y 6m
Avg Prosecution
47 currently pending
Career history
1285
Total Applications
across all art units

Statute-Specific Performance

§101
4.0%
-36.0% vs TC avg
§103
29.2%
-10.8% vs TC avg
§102
15.1%
-24.9% vs TC avg
§112
36.1%
-3.9% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1247 resolved cases

Office Action

§112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Election/Restrictions Claims 64-70 and 98-111 are pending and are examined. Information Disclosure Statement The information disclosure statements (IDS)s submitted on 04/17/2024, 12/12/2024 and 01/08/2025 were considered by the examiner. The listing of references in the specification is not a proper information disclosure statement. 37 CFR 1.98(b) requires a list of all patents, publications, or other information submitted for consideration by the Office, and MPEP § 609.04(a) states, "the list may not be incorporated into the specification but must be submitted in a separate paper." Therefore, unless the references have been cited by the examiner on form PTO-892, they have not been considered. Claim Rejections - 35 USC § 112 The following is a quotation of the first paragraph of 35 U.S.C. 112(a): (a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention. The following is a quotation of the first paragraph of pre-AIA 35 U.S.C. 112: The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor of carrying out his invention. Claims 64-70 and 98-111 are rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, as failing to comply with the written description requirement. The claims contain subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor or a joint inventor, or for applications subject to pre-AIA 35 U.S.C. 112, the inventors, at the time the application was filed, had possession of the claimed invention. “[T]he purpose of the written description requirement is to ‘ensure that the scope of the right to exclude, as set forth in the claims, does not overreach the scope of the inventor’s contribution to the field of art as described in the patent specification.’” Ariad Pharm., Inc. v. Eli Lilly & Co., 598 F.3d 1336, 1353-54 (Fed. Cir. 2010) (en banc) (quoting Univ. of Rochester v. G.D. Searle & Co., 358 F.3d 916, 920 (Fed. Cir. 2004)). To satisfy the written description requirement, the specification must describe the claimed invention in sufficient detail that one skilled in the art can reasonably conclude that the inventor had possession of the claimed invention. Vas-Cath, Inc. v. Mahurkar, 935 F.2d 1555, 1562-63, 19 USPQ2d 1111 (Fed. Cir. 1991). (emphasis added). See also MPEP 2163.04. The instant claims are drawn to a method of treating cancer comprising administering to a subject with cancer an isolated fusion polypeptide comprising a Siglec-9 extracellular domain (ECD) comprising the amino acid sequence of SEO ID NO: 78 and lacking the amino acid sequence of SEO ID NO: 147, wherein the Siglec-9 ECD is joined at its C-terminus to an Fc domain. The cancer may be a solid tumor associated with a tumor microenvironment comprising myeloid cells. The method further comprises administering an antagonist of PD-1 or PD-L1. Specific constructs are defined as being able to treat cancer. Thus, the claims are drawn to a genus of methods of treating a wide array of diseases characterized by uncontrollable growth. Cancer is the name given to a collection of related diseases characterized by cellular out of control division and spreading in the surrounding or distant tissues. Cancer can start almost anywhere in the human body, which is made up of trillions of cells. Normally, human cells grow and divide to form new cells as the body needs them. When cells grow old or become damaged, they die, and new cells take their place. When cancer develops, however, this orderly process breaks down. As cells become more and more abnormal, old or damaged cells survive when they should die, and new cells form when they are not needed. These extra cells can divide without stopping and may form growths called tumors. Many cancers form solid tumors, which are masses of tissue. Cancers of the blood, such as leukemias, generally do not form solid tumors. There are more than 100 types of cancer. Types of cancer are usually named for the organs or tissues where the cancers form. Cancers also may be described by the type of cell that formed them, such as an epithelial cell or a squamous cell. Some categories of cancers that begin in specific types of cells are:  Carcinomas- they are the most common type of cancer. They are formed by epithelial cells, which are the cells that cover the inside and outside surfaces of the body. There are many types of epithelial cells, which often have a column-like shape when viewed under a microscope. Carcinomas that begin in different epithelial cell types have specific names: o Adenocarcinoma is a cancer that forms in epithelial cells that produce fluids or mucus. Tissues with this type of epithelial cell are sometimes called glandular tissues. Most cancers of the breast, colon, and prostate are adenocarcinomas. o Basal cell carcinoma is a cancer that begins in the lower or basal (base) layer of the epidermis, which is a person's outer layer of skin. o Squamous cell carcinoma is a cancer that forms in squamous cells, which are epithelial cells that lie just beneath the outer surface of the skin. Squamous cells also line many other organs, including the stomach, intestines, lungs, bladder, and kidneys. Squamous cells look flat, like fish scales, when viewed under a microscope. Squamous cell carcinomas are sometimes called epidermoid carcinomas. o Transitional cell carcinoma is a cancer that forms in a type of epithelial tissue called transitional epithelium, or urothelium. This tissue, which is made up of many layers of epithelial cells that can get bigger and smaller, is found in the linings of the bladder, ureters, and part of the kidneys (renal pelvis), and a few other organs. Some cancers of the bladder, ureters, and kidneys are transitional cell carcinomas.  Sarcomas- they are cancers that form in bone and soft tissues, including muscle, fat, blood vessels, lymph vessels, and fibrous tissue (such as tendons and ligaments). Osteosarcoma is the most common cancer of bone. The most common types of soft tissue sarcoma are leiomyosarcoma, Kaposi sarcoma, malignant fibrous histiocytoma, liposarcoma, and dermatofibrosarcoma protuberans.  Leukemias- they are cancers that begin in the blood-forming tissue of the bone marrow. These cancers do not form solid tumors. Instead, large numbers of abnormal white blood cells (leukemia cells and leukemic blast cells) build up in the blood and bone marrow, crowding out normal blood cells. The low level of normal blood cells can make it harder for the body to get oxygen to its tissues, control bleeding, or fight infections. There are four common types of leukemia, which are grouped based on how quickly the disease gets worse (acute or chronic) and on the type of blood cell the cancer starts in (lymphoblastic or myeloid).  Lymphomas- they are cancers that begins in lymphocytes (T cells or B cells). These are disease-fighting white blood cells that are part of the immune system. In lymphoma, abnormal lymphocytes build up in lymph nodes and lymph vessels, as well as in other organs of the body. There are two main types of lymphoma: o Hodgkin lymphoma - People with this disease have abnormal lymphocytes that are called Reed-Sternberg cells. These cells usually form from 8 cells. o Non-Hodgkin lymphoma - This is a large group of cancers that start in lymphocytes. The cancers can grow quickly or slowly and can form from B cells or T cells.  Multiple myeloma is cancer that begins in plasma cells, another type of immune cell. The abnormal plasma cells, called myeloma cells, build up in the bone marrow and form tumors in bones all through the body. Multiple myeloma is also called plasma cell myeloma and Kahler disease.  Melanoma- is cancer that begins in cells that become melanocytes, which are specialized cells that make melanin (the pigment that gives skin its color). Most melanomas form on the skin, but melanomas can also form in other pigmented tissues, such as the eye.  Brain and Spinal Cord Tumors. There are different types of brain and spinal cord tumors. These tumors are named based on the type of cell in which they formed and where the tumor first formed in the central nervous system. For example, an astrocytic tumor begins in star-shaped brain cells called astrocytes, which help keep nerve cells healthy.  Germ Cell Tumors- are a type of tumor that begins in the cells that give rise to sperm or eggs.  Neuroendocrine Tumors- they form from cells that release hormones into the blood in response to a signal from the nervous system. These tumors, which may make higher-than-normal amounts of hormones, can cause many different symptoms.  Carcinoid Tumors- are a type of neuroendocrine tumor. They are slow-growing tumors that are usually found in the gastrointestinal system (most often in the rectum and small intestine). Carcinoid tumors may spread to the liver or other sites in the body, and they may secrete substances such as serotonin or prostaglandins, causing carcinoid syndrome. An abbreviated list of cancer types is presented below: A) Bone and muscle sarcomas: ■ Chondrosarcoma ■ Ewing's sarcoma ■ Malignant fibrous histiocytoma of bone/osteosarcoma ■ Osteosarcoma ■ Rhabdomyosarcoma ■ Heart cancer B) Brain and nervous system: ■ Astrocytoma ■ Brainstem glioma ■ Pilocytic astrocytoma ■ Ependymoma ■ Primitive neuroectodermal tumor ■ Cerebellar astrocytoma ■ Cerebral astrocytoma ■ Glioma ■ Medulloblastoma ■ Neuroblastoma ■ Oligodendroglioma ■ Pineal astrocytoma ■ Pituitary adenoma ■ Visual pathway and hypothalamic glioma C) Breast: ■ Breast cancer ■ Invasive lobular carcinoma ■ Tubular carcinoma ■ Invasive cribriform carcinoma ■ Medullary carcinoma ■ Male breast cancer ■ Phyllodes tumor ■ Inflammatory Breast Cancer D) Endocrine system: ■ Adrenocortical carcinoma ■ Islet cell carcinoma (endocrine pancreas) ■ Multiple endocrine neoplasia syndrome ■ Parathyroid cancer ■ Pheochromocytoma ■ Thyroid cancer ■ Merkel cell carcinoma E) Eye: ■ Uveal melanoma ■ Retinoblastoma F) Gastrointestinal ■ Anal cancer ■ Appendix cancer ■ cholangiocarcinoma ■ Carcinoid tumor, gastrointestinal ■ Colon cancer ■ Extrahepatic bile duct cancer ■ Gallbladder cancer ■ Gastric (stomach) cancer ■ Gastrointestinal carcinoid tumor ■ Gastrointestinal stromal tumor (GIST) ■ Hepatocellular cancer ■ Pancreatic cancer, islet cell ■ Rectal cancer G) Genitourinary and gynecologic ■ Bladder cancer ■ Cervical cancer ■ Endometrial cancer ■ Extragonadal germ cell tumor ■ Ovarian cancer ■ Ovarian epithelial cancer (surface epithelial-stromal tumor) ■ Ovarian germ cell tumor ■ Penile cancer ■ Renal cell carcinoma ■ Renal pelvis and ureter, transitional cell cancer ■ Prostate cancer ■ Testicular cancer ■ Gestational trophoblastic tumor ■ Ureter and renal pelvis, transitional cell cancer ■ Urethral cancer ■ Uterine sarcoma ■ Vaginal cancer ■ Vulvar cancer ■Wilms tumor F) Head and neck ■ Esophageal cancer ■ Head and neck cancer ■ Nasopharyngeal carcinoma ■ Oral cancer ■ Oropharyngeal cancer ■ Paranasal sinus and nasal cavity cancer ■ Pharyngeal cancer ■ Salivary gland cancer ■Hypopharyngeal cancer G) Hematopoietic ■ Acute biphenotypic leukemia ■ Acute eosinophilic leukemia ■ Acute lymphoblastic leukemia ■ Acute myeloid leukemia ■ Acute myeloid dendritic cell leukemia ■ AIDS-related lymphoma ■ Anaplastic large cell lymphoma ■ Angioimmunoblastic T-cell lymphoma ■ B-cell prolymphocytic leukemia ■ Burkitt's lymphoma ■ Chronic lymphocytic leukemia ■ Chronic myelogenous leukemia ■ Cutaneous T-cell lymphoma ■ Diffuse large B-cell lymphoma ■ Follicular lymphoma ■ Hairy cell leukemia ■ Hepatosplenic T-cell lymphoma ■ Hodgkin's lymphoma ■ Hairy cell leukemia ■ lntravascular large 8-cell lymphoma ■ Large granular lymphocytic leukemia ■ Lymphoplasmacytic lymphoma ■ Lymphomatoid granulomatosis ■ Mantle cell lymphoma ■ Marginal zone 8-cell lymphoma ■ Mast cell leukemia ■ Mediastinal large B cell lymphoma ■ Multiple myeloma/plasma cell neoplasm ■ Myelodysplastic syndromes ■ Mucosa-associated lymphoid tissue lymphoma ■ Mycosis fungoides ■ Nodal marginal zone B cell lymphoma ■ Non-Hodgkin lymphoma ■ Precursor B lymphoblastic leukemia ■ Primary central nervous system lymphoma ■ Primary cutaneous follicular lymphoma ■ Primary cutaneous immunocytoma ■ Primary effusion lymphoma ■ Plasmablastic lymphoma ■ Sezary syndrome ■ Splenic marginal zone lymphoma ■ T-cell prolymphocytic leukemia H) Skin ■ Basal cell carcinoma ■ Squamous cell carcinoma ■ Skin adnexal tumors (e.g. sebaceous carcinoma) ■ Melanoma ■ Merkel cell carcinoma ■ Sarcomas of primary cutaneous origin (e.g. dermatofibrosarcoma protuberans) ■ Lymphomas of primary cutaneous origin (e.g. mycosis fungoides) I) Thoracic and respiratory ■ Bronchial adenomas/carcinoids ■ Small cell lung cancer ■ Mesothelioma ■ Non-small cell lung cancer ■ Pleuropulmonary blastoma ■ Laryngeal cancer ■ Thymoma and thymic carcinoma J) HIV/ AIDS related ■ AIDS-related cancers ■ Kaposi sarcoma K) Unsorted ■ Epithelioid hemangioendothelioma (EHE) ■ Desmoplastic small round cell tumor ■ Liposarcoma (https://en.wikipedia.org/wiki/List_of_cancer_types- accessed 05/22/2020; https://www.cancer.gov/about-cancer/understanding/what-is-cancer). This represents a short list of the diseases that are to be treated by the method of treatment claimed by the instant Application and is illustrative of the breadth of claims. Further, any method of treatment comprises the composition to be administered, a range dosage per kg or m2, a treatment regimen and metrics for determining if the goal of the treatment has been achieved. The specification does not address these parameters. Examples in the specification are drawn to treating mice with xenografts of human cancer cells of colon, breast and melanoma. However, Applicant is claiming treatment of every type of cancer and the treatment of three types of cancer does not indicate a representative number of species of the methods of treatment claimed. A "representative number of species" means that those species that are adequately described are representative of the entire genus. AbbVie Deutsch/and GMBH v. Janssen Biotech, 111 USPQ2d 1780, 1790 (Fed. Cir. 2014). When there is substantial variation within the genus, one must describe a sufficient variety of species to reflect the variation within the genus to provide a "representative number" of species. In Amgen Inc. v. Sanofi, 124 USPQ2d 1354 (Fed. Cir. 2017), relying upon Ariad Pharms., Inc. v. Eli Lily & Co., 94 USPQ2d 1161 (Fed Cir. 2010), it is noted that to show invention , a patentee must convey in its disclosure that is "had possession of the claimed subject matter as of the filing date”. Given the well-known number of types of cancers each with different etiologies and treatment options the skilled artisan would not have been in possession of the vast repertoire of methods of treatment that may be used in the genus of methods claimed. One of skill in the art would conclude that the specification fails to disclose a representative number of species to describe the claimed genera. Conclusion No claims are allowed. Any inquiry concerning this communication or earlier communications from the examiner should be directed to ELLY GERALD STOICA whose telephone number is (571)272-9941. The examiner can normally be reached M-F 8-5 EST. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Joanne Hama can be reached at 571-272-2911. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. ELLY-GERALD STOICA Primary Examiner Art Unit 1647 /Elly-Gerald Stoica/Primary Examiner, Art Unit 1647
Read full office action

Prosecution Timeline

Apr 17, 2024
Application Filed
Oct 27, 2026
Non-Final Rejection mailed — §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12774328
METHOD OF TREATMENT OF A TUMOR WITH IL-8 ANTIBODY
3y 5m to grant Granted Oct 27, 2026
Patent 12767724
THERAPEUTIC DRUG FOR CARCINOMATOUS PERITONITIS
4y 4m to grant Granted Oct 20, 2026
Patent 12758623
ANTI-GUCY2C VACCINES AND VACCINATION
4y 5m to grant Granted Oct 13, 2026
Patent 12758616
PM21 PARTICLES TO IMPROVE BONE MARROW HOMING OF NK CELLS
3y 4m to grant Granted Oct 13, 2026
Patent 12751999
LIPID NANOPARTICLES
3y 10m to grant Granted Oct 06, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
67%
Grant Probability
89%
With Interview (+22.6%)
2y 6m (~0m remaining)
Median Time to Grant
Low
PTA Risk
Based on 1247 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month